Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.

In a subgroup analysis of the TEMSO trial, teriflunomide 14 mg showed a trend towards a greater effect on the risk of disability progression in patients with higher baseline EDSS scores (> 3.5) compared with those with lower scores; ARR was reduced most in patients with lower EDSS at baseline [ 13 ].

also in 53,322 other papers